VEGF-C human
SIGMA/SRP4633 - recombinant, expressed in E. coli, ≥90% (SDS-PAGE)
Synonym: VEGFC; Vascular Endothelial Growth Factor-C
MDL Number: MFCD03458368
Product Type: Chemical
VEGF Pathway Research areas: Angiogenesis, Metastasis, Hypoxia, Osteogenesis, Developmental biology Disease areas: Cancer, Osteoporosis, Ischemic stroke, Inflammation, Rheumatoid Arthritis, Diabetes See also: SRP3182; SRP4363; V5765; SRP4634; SRP4364; SRP4365, SRP3184
| assay | ≥90% (SDS-PAGE) |
| biological source | human |
| form | lyophilized |
| impurities | endotoxin, tested |
| mol wt | 15-16 kDa |
| NCBI accession no. | Q6FH59   |
| packaging | pkg of 10 μg |
| recombinant | expressed in E. coli |
| shipped in | wet ice |
| storage condition | avoid repeated freeze/thaw cycles |
| storage temp. | −20°C |
| Application: | VEGF-C human has been used to determine cell proliferation and survival. |
| Biochem/physiol Actions: | VEGF-C (vascular endothelial growth factor-C) promotes tumorigenesis, by inducing lymphatic metastasis. The production of VEGF-C is stimulated by pro-fibrotic transforming growth factor β. The main function of VEGF-C is to mediate lymphangiogenesis. Overexpression of VEGF-C in keratinocytes of skin causes dermal lymphatic vessel hyperplasia. |
| General description: | The recombinant VEGF-C (vascular endothelial growth factor-C) is a 125 amino acid protein that lacks the N-terminal signal peptide (from T103 to R227 of Gene Bank U58111). Human VEGF-C exhibits about 85% homology with mouse VEGF-C. The VEGFC gene is mapped to human chromosome 4q34.3. |
| Physical form: | Lyophilized without additives. |
| Reconstitution: | Centrifuge the vial prior to opening. Avoid freeze-thaw cycles. |
| Reconstitution: | Reconstitute in 0.1% acetic acid to a concentration of 0.1-1.0 mg/mL. |
| RIDADR | NONH for all modes of transport |
| WGK Germany | WGK 3 |
| Flash Point(F) | Not applicable |
| Flash Point(C) | Not applicable |
| Purity | ≥90% (SDS-PAGE) |
| Storage Temp. | −20°C |
| UNSPSC | 12352200 |